linjc16/ctgov huggingface dataset:
Analysis of 2560 Theses

Study Overview
=================
Brief Summary
-----------------
Thesis publication rates in our country, according to research other medical branches; in psychiatry thesis % 37,4; Family Medicine, an increase of 0.9%; in emergency medicine and 7.3% in public health 1.5%; in microbiology %4,2; 5.7 percent in urology; brain surgery was 6.8%; general surgery 5%; 3.8% in eye diseases and surgery; ear, nose and throat diseases and surgery, in %4,2 as has been reported.

Official Title
-----------------
Publication Rates of Theses in the Field of Anesthesiology and Reanimation in Turkey; Analysis of 2563 Theses

Conditions
-----------------
Publication Rates

Intervention / Treatment
-----------------
* Behavioral: publication rates


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the keywords anesthesiology and reanimation Made between 2000 and 2018, theses whose complete data can be accessed and allowed to be accessed by authors over the internet Exclusion Criteria: theses whose complete data can be accessed and whose access is not allowed by the authors over the internet.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: publication rates|publication rates of theses produced in the Department of Anesthesiology and reanimation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| publication rate | publication rates of theses produced in the Department of Anesthesiology and reanimation | 2 month |
Influenza Vaccination and Oral Anticoagulant Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate INR and INR related index and Warfarin weekly dosage variations after Influenza Vaccination

Detailed Description
-----------------
The pharmacokinetic and the pharmacodynamic interactions and the possible clinical events connected with the simultaneous administration of Oral Anticoagulants (OA) and the influenza virus vaccine were evaluated in several small studies which yielded conflicting results, thus encouraging additional investigations with prospective studies in order to obtain a more consistent evidence about the safety and efficacy of vaccination against influenza virus in patients on OA Treatment.

Official Title
-----------------
Randomized Blinded Cross-Over Clinical Trial Investigate the Interactions Between Influenza Vaccination and Oral Anticoagulant Therapy

Conditions
-----------------
Anticoagulants, Influenza Vaccines

Intervention / Treatment
-----------------
* Drug: Influenza vaccination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: OA Treatment Stable anticoagulation (previous two controls in range) Presence of indication for Influenza Vaccination Life expectancy > 6 months Signed Informed consent Exclusion Criteria: Absence of stable anticoagulation Absence of indication for Influenza Vaccination Life expectancy < 6 months Denied Informed Consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Influenza vaccination|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1.Variations in INR value and in OAT weekly dosage after IV |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1.Efficacy of IV in patients on OAT |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral anticoagulants, Influenza virus, Influenza vaccine, Pharmacological interference
Early Identification and Prognosis Prediction of Sepsis Through Multiomics

Study Overview
=================
Brief Summary
-----------------
This study aims to integrate multi-omics data and clinical indicators to reveal pathogen-specific molecular patterns in patients with sepsis and establish prognostic prediction models through multiple machine learning algorithms.

Detailed Description
-----------------
This study aims to quantify the plasma metabolome, single nucleotide polymorphisms (SNPs) of exons and immunocytokines of septic patients with different pathogen infections and prognostic outcomes. Multi-omics data, cytokines, and clinical indicators will be integrated through multiple machine learning algorithms to reveal pathogen-specific molecular patterns and multi-dimensional prognostic prediction models.

Official Title
-----------------
Early Identification and Prognosis Prediction of Sepsis Through Multiomics

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with sepsis or septic shock who meet the diagnostic criteria (2016 sepsis 3.0 standard); Age 18～85 years old. Exclusion Criteria: ICU stay of the subjects less than 72 hours; Female subjects who are pregnant; The subjects not sure if infected; The subjects performed CPR; The subjects suffer from chronic renal disease; The subjects with incomplete clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GN<br>Gram-negative bacteria infection group | |
| GP<br>Gram-positive bacteria infection group | |
| Fungal<br>Fungal infection group | |
| Viral<br>Viral infection group | |
| Control<br>Non-sepsis group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathogen-specific patterns | To elucidate the unique infection pathogen-specific molecular patterns in septic patients | March 2022 - December 2023 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognostic prediction models | To establish the models using multi-omics data to predict the prognosis of sepsis | March 2022 - December 2024 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prognosis, Inflammation, Immune, Multiomics, Machine learning
Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

Official Title
-----------------
Efficacy and Safety of Initiation of Biphasic Insulin Aspart 30 Treatment in Subjects With Type 2 Diabetes Mellitus Failing OAD Therapy

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes for at least 24 months BMI between 18 and 30 kg/m2 Insulin naive subjects OAD treatment with max two OADs alone or combined with other therapy HbA1c between 7-12% Exclusion Criteria: Type 1 diabetes Receipt of any investigational drug within the last three months prior to this trial Current or previous treatment with thiazolidiones within the last 6 months OAD treatment with three or more OADs within the last 4 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: biphasic insulin aspart|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 11 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of subjects achieving treatment target of HbA1c below 7% |  | at 11 and 24 weeks | 
| 8-point plasma glucose profiles |  | performed at 11 and 24 weeks | 
| FPG |  | at 11 weeks and 24 weeks |
A Combination Therapy In Patients With Social Anxiety Disorder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)

Official Title
-----------------
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)

Conditions
-----------------
Social Phobia

Intervention / Treatment
-----------------
* Drug: vestipitant/paroxetine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Primary diagnosis of Generalised Social Anxiety Disorder as defined in DSM-IV. Capable of giving informed consent and willing to comply with the study requirements. Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control. Exclusion criteria: Primary diagnosis within the past 6 months of another Axis 1 disorder such as Major Depression or another anxiety disorder. Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type. Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine). Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: vestipitant/paroxetine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SAD, anxiety, Social Anxiety Disorder
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease

Study Overview
=================
Brief Summary
-----------------
More than one million people in Europe suffer from a stroke every day. Normally older people have a stroke, but also a significant number of younger people between 18 and 55 years. Usually, these can only be explained for a minority by the classical risk factors such as diabetes, overweight and high blood pressure. New studies indicate that in about 1 - 2 % of the younger stroke patients the etiology can be an undiagnosed genetic disease, e.g. Fabry disease. Fabry disease is a lysosomal storage disorder known to cause vasculopathy. The purpose of this study is to determine in a large number of young stroke patients, how many strokes were caused by Fabry disease and what risk factors might be able to predict this disease.

Official Title
-----------------
FASEP Fabry and Stroke Epidemiological Protocol RISK FACTORS IN ISCHEMIC STROKE PATIENTS WITH FABRY DISEASE AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

Conditions
-----------------
Cerebrovascular Accident, Stroke, Acute, Cerebral Stroke

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (18 - 60 years of age) with an acute ischemic cerebrovascular event either acute ischemic stroke or transient ischemic attack within 10 days Diagnosis of the cerebrovascular event (CVE) by a stroke experienced physician Diagnostic procedures for CVE according to the local guidelines and recommendations Written informed consent from patient or legal representative according to local regulations Exclusion Criteria: Patients being younger than 18 years or older than 60 years of age. Acute ischemic stroke or transient ischemic attack longer than 10 days before enrollment into the study CVE associated with intracranial hemorrhage as evidenced by cerebral CT scan Any uncertainty in the diagnosis No written informed consent from the patient or legal representative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation<br>all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebrovascular Accident, Cerebrovascular Accident, Acute, Fabry Disease, Fabry´s Disease, Anderson-Fabry Disease, CVA (Cerebrovascular Accident), Stroke, Acute, Cerebral Stroke
Clinical Image Evaluation for the DREX-KL80 Imaging System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to acquire the clinical data required by the United States Food and Drug Administration (USFDA) for 510(k) submission, for approval of a new high resolution imaging system for fluoroscopy/radiography. It is expected that the new KALARE (DREX-KL80)high resolution imaging system will meet the design specifications. A minimum of 30 cases will be submitted for evaluation of claims for intended clinical applications.

Official Title
-----------------
Clinical Image Evaluation for the KALARE (DREX-KL80) With New Digital Camera and Image Processor

Conditions
-----------------
Obtain Diagnostic Images With the New Digital Camera and Image Processor for Evaluation.

Intervention / Treatment
-----------------
* Device: Radiography and Fluoroscopy Imaging System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patient 18 years and older Not pregnant Not a safety risk patient Exclusion Criteria: Male and female patient under 18 years old Pregnant subjects High safety risk subjects Subjects and/or Legal Guardian Unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fluoroscopy and Angiography Procedure<br>Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician. | Device: Radiography and Fluoroscopy Imaging System<br>* KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format. The system includes a new digital camera and a new image processor.<br>* Other names: KALARE (DREX-KL80);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of representative images | Collect 30 to 60 represenative images to support pre-market submission. | Estimated completion 4 weeks after start of the study |
Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.

Official Title
-----------------
Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

Conditions
-----------------
Insulin Resistance, Diabetes, End Stage Renal Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemodialysis for End Stage Renal Disease group Normal Renal Function for Control group Exclusion Criteria: Diabetes Malnutrition Malignancy Acute Infection Chronic Active Infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| End Stage Renal Disease<br>Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes | |
| Control<br>Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinol Binding Protein 4, Insulin Resistance, Diabetes, End Stage Renal Disease, Dialysis, Nutrition
Association of Survival in Impact of Ultrafiltration Rates in Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
This study assesses retrospectively the association of mortality on UFR assessments in our study population undergoing HD.

Official Title
-----------------
Impact of Ultrafiltration Rates on Mortality in Maintenance Hemodialysis Patients

Conditions
-----------------
Hemodialysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with stable undergoing hemodialysis for >1 year. Exclusion Criteria: Patients with combined therapy with peritoneal dialysis and HD. Patients without records of laboratory investigations during this period. Patients with transferred hospital and those lost to follow-up.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrafiltration rate (ml/hr/kg) |  | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ultrafiltration rate
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor

Study Overview
=================
Brief Summary
-----------------
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran exposure (in Part II)

Official Title
-----------------
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: dabigatran etexilate
* Drug: dabigatran etexilate
* Drug: ticagrelor
* Drug: ticagrelor
* Drug: ticagrelor
* Drug: dabigatran etexilate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: 1. Healthy male subjects. Exclusion criteria: 1. Any relevant deviation from healthy conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Reference (Part 1/A, Part 2/C)<br>multiple doses of dabigatran (alone) | Drug: dabigatran etexilate<br>* medium dose dabigatran<br>|
| Experimental: Test 1 (Part 1/Treatment B)<br>concomitant administration of dabigatran and ticagrelor | Drug: dabigatran etexilate<br>* multiple doses of dabigatran<br>Drug: ticagrelor<br>* loading dose of ticagrelor<br>Drug: ticagrelor<br>* multiple doses of ticagrelor<br>|
| Experimental: Test 2 (Part 2/Treatment D)<br>staggered administration of ticagrelor and dabigatran | Drug: ticagrelor<br>* loading dose of ticagrelor<br>Drug: dabigatran etexilate<br>* single dose of dabigatran<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Dabigatran: Area Under the Concentration-time Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss) | Area under the concentration-time curve of dabigatran etexilate in plasma at steady state over the uniform dosing interval τ (AUCτ,ss). | 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours | 
| Total Dabigatran: Maximum Measured Concentration at Steady State (Cmax,ss) | Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss). | 47.55, 48.30,49, 49.30,50,50.30,51,52,54,56, 60 hours |